Alzheimer’s disease, frontotemporal dementias, progressive supranuclear palsy, Corticobasal degeneration, Clinical Trial Study
< Back to Find a Trial

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer’s Disease (221AD301)

ID
NCT02477800
Condition Studied
Alzheimer's Disease
Phase
Phase III
Status
Closed
Intervention
Aducanumab (BIIB037)
Principal Investigator
Sponsor
Biogen

Please go to ClinicalTrials.gov for more information.